Stock Events

Stock Events

Alimera Sciences 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals competes with Alimera in the macular degeneration and diabetic macular edema treatment market, particularly with its Eylea product.
Novartis
NVS
Mkt Cap268B
Novartis is a direct competitor in the ophthalmology space, offering products like Lucentis for macular degeneration, which competes with Alimera's treatments.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech division, competes in the market for eye diseases, including macular degeneration and diabetic eye disease treatments.
Bausch Health Companies
BHC
Mkt Cap2.17B
Bausch Health Companies, formerly Valeant Pharmaceuticals, offers a range of ophthalmic products that compete with Alimera's portfolio.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie, through its acquisition of Allergan, has a presence in the ophthalmology market, competing with Alimera Sciences in providing treatments for eye conditions.
Pfizer
PFE
Mkt Cap158.45B
Pfizer has been involved in developing treatments for eye diseases, including investments in gene therapy for inherited retinal disorders, positioning it as a competitor.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its Janssen Pharmaceuticals division, is involved in research and development of treatments for eye diseases, competing with Alimera.
Biogen
BIIB
Mkt Cap32.49B
Biogen has ventured into ophthalmology with its pipeline in gene therapy for inherited retinal diseases, making it a potential competitor to Alimera.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline has shown interest in expanding its portfolio into ophthalmology, potentially competing with Alimera Sciences in the future.

About

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Show More
CEO
Richard Eiswirth
Employees
154
Country
United States
ISIN
US0162591038
WKN
000A2PVHE

Listings

STU
DE
ASZ.STU

0 Comments

Share your thoughts

FAQs

What is Alimera Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Alimera Sciences stocks are traded under the ticker ASZ.STU.
How many employees does Alimera Sciences have?▼
As of November 1, 2026, the company has 154 employees.
In which sector is Alimera Sciences located?▼
Alimera Sciences operates in the Technology sector.
When did Alimera Sciences complete a stock split?▼
The last stock split for Alimera Sciences was on November 15, 2019 with a ratio of 1:15.
Where is Alimera Sciences headquartered?▼
Alimera Sciences is headquartered in Alpharetta, United States.